The trial will compare the effects of an optimized background drug regimen alone with an optimized background regimen plus SQ109 in MDR-TB patients.

Several interventions for tuberculosis (TB) control have been recommended by the World Health Organization (WHO) over the past decade. These include isoniazid preventive therapy (IPT) for HIV-infected individuals and household contacts of infectious TB patients, diagnostic algorithms for rule-in or rule-out of smear-negative pulmonary TB, and programmatic treatment for multidrug-resistant TB. There is no systematically collected data on the type of evidence that is publicly available to guide the scale-up of these interventions in low- and middle-income countries. We investigated the availability of published evidence on their effectiveness, delivery, and cost-effectiveness that policy makers need for scaling-up these interventions at country level.

One third of the world is infected with the bacterium that causes tuberculosis (TB), a disease that is increasingly difficult to treat because of wide spread resistance to available drugs. Researchers from the Institute of Pharmacology and Structural Biology (CNRS, Université de Toulouse) in Toulouse (France) have identified a fresh target to develop new drugs for TB. The study, published in the Open Access journal PLOS Pathogens, shows why the target will be important in developing new TB treatments.

Bethesda, MD—A drug currently being used to treat ischemic strokes may prove to be a significant advance in the treatment of tuberculosis and ulcers. In a new research report appearing online in The FASEB Journal, a compound called ebselen effectively inhibits the thioredoxin reductase system in a wide variety of bacteria, including Helicobacter pylori which causes gastric ulcers and Mycobacterium tuberculosis which causes tuberculosis. Thioredoxin and thioredoxin reductase proteins are essential for bacteria to make new DNA, and protect them against oxidative stress caused by the immune system. Targeting this system with ebselen, and others compounds like it, represents a new approach toward eradicating these bacteria.

Hubbard, OH -December 17, 2012 -- NanoLogix (OTC Markets: NNLX) An independent third-party study by one of the foremost Biomedical Research centers in the U.S has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

The Union published its official statement on TB prevention and control measures that should be taken on behalf of the 9.8 million people in jails, prisons, remand and detention centres worldwide.

Grant to reshape market forces, catalyze development to improve treatment of childhood TB.

Pilot TB-HIV programmes have demonstrated that integrated care provided through primary health care facilities, using paramedical staff, is feasible and effective.

A joint Union/MSF publication providing transparent information on prices and quality-assured sources for DR-TB medicines, as well as a summary of the challenges still limiting their access to a broader number of patients.

NASHVILLE, Tenn.—Natalie Skipper started feeling under the weather a few weeks after returning home from volunteering at a South Africa hospital. "The worst flu I had ever had in my life," she said.